Avalyn Pharma Inc. (AVLN) vs Generate Biomedicines, Inc. (GENB)

Avalyn Pharma Inc. and Generate Biomedicines, Inc. are both Biotechnology companies. Avalyn Pharma Inc. and Generate Biomedicines, Inc. are of similar size ($1.3B and $1.2B). Avalyn Pharma Inc. has the higher net margin (0.00% vs −1,381.8%) and the lower return on invested capital (−127.6% vs 0.00%). Across the 11 metrics below, Avalyn Pharma Inc. leads on 6 and Generate Biomedicines, Inc. on 5.

Valuation

Metric AVLN GENB Biotechnology median
P/E n/m n/m 10.01
P/S n/m 59.96 9.02
P/B 3.34 3.31 2.13
Price to free cash flow n/m n/m 24.99
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 41.05 9.01
Earnings yield (157.17%) (42.17%) (34.01%)
Free cash flow yield (8.11%) (20.00%) (24.62%)

Profitability

Metric AVLN GENB Biotechnology median
Gross margin — 100.00% 70.18%
Operating margin 0.00% (1,382.04%) 0.00%
Net margin 0.00% (1,381.76%) 0.00%
Free cash flow margin 0.00% (1,199.36%) 0.00%
Return on equity 0.00% 1,091.11% (50.72%)
Return on assets 0.00% (56.30%) (45.56%)
Return on invested capital (127.60%) 0.00% 0.00%

Growth

Metric AVLN GENB Biotechnology median
Revenue growth (TTM) — — 7.42%
EPS growth (last fiscal year) — (13.66%) 29.36%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric AVLN GENB Biotechnology median
Debt to equity 0.04 0.02 0.00
Current ratio 25.76 5.01 4.72
Net debt to EBITDA — 0.97 1.01

Dividend

Metric AVLN GENB Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric AVLN GENB Biotechnology median
Market cap 1.24b 1.27b 157.22m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack